Chimerix
- Home
- News & Resources
- Archive
2006
Chimerix Announced Initiation of Phase I clinical trials of CMX001, An Oral Treatment for Smallpox Infection
15.16 KB
RESEARCH TRIANGLE PARK, NC, June 28 2006 - Chimerix, Inc., a biotechnology company developing orally available antiviral therapeutics, announced today that it has received U.S. Food and Drug Administration clearance for its Investigational New Drug…
Chimerix Acquires Lead Compound Library of Antiviral Agents from University of Michigan
18.41 KB
RESEARCH TRIANGLE PARK, NC, May 24 2006 - Chimerix, Inc., an emerging biotechnology company developing orally available antiviral therapeutics, announced today that it has acquired Dr. Leroy Townsend’s lifetime library of chemical lead compounds from the University…
Chimerix and USAMRIID Collaborate to Complete Preclinical Development of Smallpox Therapeutic
18.40 KB
RESEARCH TRIANGLE PARK, NC, April 18, 2006 - Chimerix, Inc., a biotechnology company developing orally available, targeted medicines to treat smallpox and other viral infections, announced today that it has signed a Cooperative Research and Development Agreement (CRADA)…
2005
Chimerix, Inc. Announces Selection As A Top 5 Nominee For 2005 World Technology Award In Health And Medicine
15.71 KB
RESEARCH TRIANGLE PARK, NC, November 10, 2005 - Chimerix, Inc., a biotechnology company developing orally available, targeted medicines to treat smallpox and other viral infections, announced today that the company has been selected as one of the top five nominees…
Chimerix, Inc. Supports Biodefense Legislation to Accelerate and Innovate Counterterrorism Products
15.96 KB
RESEARCH TRIANGLE PARK, NC, November 3, 2005 - Chimerix, Inc., a biotechnology company developing orally available, targeted medicines to treat smallpox infection and other viral infections, announced today support for S. 1873, the Biodefense and Pandemic Vaccine and Drug Development…
Chimerix Named a Red Herring Top 100 Private Company
19.14 KB
- Award Recognizes Chimerix as a Top Company in North America
that Drives the Technology Industry’s Future -
SAN DIEGO, CA, May 12, 2005 - Chimerix Inc., an emerging biotechnology company developing orally available antiviral therapeutics, today…
2004
Chimerix Raises $11 Million
20.86 KB
SAN DIEGO, CA, November 4, 2004 - Chimerix Inc., an emerging biotechnology company developing orally available antiviral therapeutics, today announced an $11 million private placement of its Series C preferred stock. Frazier Healthcare Ventures, a new investor, led the round, and…
Chimerix Granted Patent for CMX001
16.00 KB
SAN DIEGO, CA, April 27, 2004 – Chimerix, Inc. and the University of California, San Diego (UCSD) announced today the issuance of U.S. Patent No. 6,716,825 entitled “Phosphonate Compounds” by the U.S. Patent and Trademark Office. The patent claims novel phosphonate…
Chimerix Awarded NIH Grant
16.45 KB
SAN DIEGO, CA, March 11, 2004 - Chimerix Inc., a biotechnology company developing orally available, targeted medicines for the treatment of smallpox, multi-drug resistant HIV and hepatitis virus infections, today announced that it has been awarded a Phase I Small Business Innovation…
2003
Chimerix Announces Licensing Deal
19.33 KB
- Chimerix Obtains Rights to Cidofovir for Development of an Oral Drug to Treat Smallpox Infections -
SAN DIEGO, CA, September 12, 2003 - Chimerix Inc., an emerging biotechnology company developing orally available, targeted medicines from bioactive molecules, today…
‹ First < 4 5 6 7 >